Sitagliptin cardiovascular outcomes study mk0431082. New tecos analysis adds heart failure data for sitagliptin. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin, sold under the brand name januvia among others, is a medication used to treat diabetes mellitus type 2. Cardiovascular risk of sitagliptin in ischemic stroke. Sitagliptin is a prescription medication used with a proper diet and exercise program and possibly with other medications to control high blood sugar. Randomised, placebocontrolled global clinical trial performed in 14,735 patients who were enrolled between 2009 and 2012. The fda has rejected a supplemental new drug application for mercks dppiv inhibitor sitagliptin, which sought to include recent cardiovascular outcomes trial data in its prescribing. A new analysis of the tecos study has shown that patients with type2 diabetes and cardiovascular disease can safely take the antihyperglycaemic drug sitagliptin without an increased risk of cardiovascular complications even if they have a history of heart failure. Drug information table gliptins sitagliptin januvia.
For those who had a withintrial mi, we analyzed case fatality. The aim of the present post hoc analysiswastoevaluatecvandckdout. In clinical trials of 1year duration, sitagliptin improved glycaemic. We used data from 14 671 participants in the tecos study who were randomized doubleblind to sitagliptin n 7332 or placebo n 7339. View detailed export data, price, monthly trends, major exporting countries, major ports of sitagliptin. Sitagliptin does not reduce the risk of cardiovascular.
The findings, presented today at esc congress 2015, provide reassurance to patients and prescribers about the cardiovascular safety of sitagliptin a dipeptidyl peptidase4 dpp4 inhibitor. Tecos randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular disease ascvd to sitagliptin or placebo, in addition to usual care. Tecos analysis adds heart failure data for sitagliptin. Tecos cannot claim any cardiovascular protection with sitagliptin, but the point is the trial illustrated a lack of harm, said dr mcguire, and this was, after all, the main initial impetus for. Pancreatic safety of sitagliptin in the tecos study. Listing a study does not mean it has been evaluated by the u. Januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Frontiers saxagliptin but not sitagliptin inhibits. Sitagliptin januvia cv outcomes trial summary 1 sitagliptin. Some oral antihyperglycemic drugs, including gliptins that inhibit dipeptidyl peptidase 4 dpp4, have been linked to the increased risk of heart failure hf in type2 diabetic patients.
In the trial evaluating cardiovascular outcomes with sitagliptin tecos, a cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis and. To examine the effects of the dpp4i sitagliptin on cv outcomes during and after incident mi in the trial evaluating cardiovascular outcomes with sitagliptin tecos. Sitagliptin is a substrate for human organic anion transporter3 hoat3, which may be involved in the renal elimination of sitagliptin. Effect of sitagliptin on kidney function and respective. Another placebocontrolled study gave sitagliptin to 741 patients for 24 weeks. Check with your physician if you have any of the following. Cardiovascular cv outcomes and mortality in patients with type 2 diabetes mellitus t2dm in patients with t2dm and at high risk of cv events, does sitagliptin reduce cv risk compared to placebo when added to standard care. Effect of sitagliptin on blood glucose control in patients. Proper control of diabetes may also lessen your risk of a heart attack or. A wide variety of sitagliptin intermediate options are available to you, such as grade standard. Trial evaluating cardiovascular outcomes with sitagliptin. Januvia is a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adultswith type 2 diabetes mellitus.
In the united kingdom it is listed as less preferred than metformin or a sulfonylurea. Sitagliptin oral tablet is available as the brandname drug januvia. Drug information table gliptins sitagliptin januvia therapeutic use administration treats type 2 diabetes alone or in combination with other drugs for diabetes administer orally alone or in combination with metformin janumet. Outcomes with sitagliptin tecos 9 showedthataddingsitagliptin,compared with placebo, to usual care in patients with type 2 diabetes and established cv diseasedidnothaveanimpactontherisk of major cv outcomes, hospitalization for heart failure, or adverse events in general. Sitagliptin helps to control blood sugar levels by increasing substances in the body that make the pancreas release more insulin. The tecos was a randomised study in 14,671 patients in the intentiontotreat population with an hba 1c of. Effect of sitagliptin on cardiovascular outcomes in type 2. To examine fracture incidence among participants in the trial evaluating cardiovascular outcomes with sitagliptin tecos. To analyze effects on hospitalization for heart failure and related outcomes objectives of tecos. To investigate the ameliorating effect of sitagliptin, a dipeptidyl peptidase4 inhibitor, on blood glucose control in patients with type 2 diabetes mellitus who were previously untreated with or who have a poor responsive to existing antidiabetic drugs. Limitations of use januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic.
Sitagliptin 50 mgday was added on to the preexisting therapy for type 2 diabetes and changes in the glycated hemoglobin hba1c level. It is also available within a single pill as metforminsitagliptin. Other continued or sitagliptin metformin of which n58 cases were hospitalized n4 cases admitted to the icu, n2 cases of hemorrhagic or necrotizing pancreatitis. Sitagliptin oral tablet is a prescription medication used to treat high blood sugar levels caused by type 2 diabetes. In the trial evaluating cardiovascular outcomes with sitagliptin tecos, we assessed the longterm cardiovascular safety of adding sitagliptin to usual care, as compared with usual care alone, in patients with type 2 diabetes and established cardiovascular disease. Sitagliptin cardiovascular outcomes study mk0431082 tecos the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Xelevia is approved in more than countries worldwide as monotherapy and in combination with other antihyperglycaemic drugs for the treatment of adult patients with type 2 diabetes t2d. Sitagliptin and risk of fractures in type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Supplementary appendix this appendix has been provided by the authors to give readers additional information about their work.
Impact of sitagliptin on heart failure and related outcomes. Updated the tecos study showed sitagliptin was not associated with any signal of cardiovascular risk and, importantly, absolutely no increase in the risk of heart failure, a signal that has. While the cardiovascular safety trial, tecos, revealed no link between sitagliptin and the risk of hf, a substantial 27% increase in the hospitalization for hf was observed in type2 diabetic patients. Highlights of prescribing information januvia safely and. The trial evaluating cardiovascular outcomes with sitagliptin tecos is the third completed dpp4i, largescale, randomized cv outcomes trial. In april, 2007 fda approved the combination product of sitaglibtin and metformin for type 2 diabetes 8. Find patient medical information for sitagliptin oral on webmd including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Sitagliptin was well tolerated and no hypoglycemiareported. About 7% of these are cardiovascular agents, 0% are antineoplastic agents, and 1% are endocrine system agents. Limited data are available about the cardiovascular cv safety and efficacy of sitagliptin, a dipeptidyl peptidase4 dpp4 inhibitor, in ischemic stroke patients with type 2 diabetes mellitus t2dm and chronic kidney disease ckd. Januvia 25mg, 50mg, 100mg filmcoated tablets summary of. The recommended dose of sitagliptin is 100 mg once daily.
After 12 weeks a total daily dose of sitagliptin 100 mg had reduced the hba1c by 0. This secondary analysis of the trial evaluating cardiovascular outcomes with sitagliptin tecos assesses the association of sitagliptin use with hospitalization for heart failure and related outcomes among patients with type 2 diabetes mellitus and atherosclerotic vascular disease. Sitagliptin cardiovascular outcomes study mk 0431082 tecos the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Sitagliptin is currently approved in 42 countries 7. Tecos evaluated the longterm effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. A comparative and critical analysis after tecos article pdf available in journal of diabetes research august 2015 with 384 reads how we measure reads. This hypoglycemic drug is commercially available in coated tablets containing 25, 50, and 100 mg of sitagliptin base. Association between sitagliptin use and heart failure.
Green and bethel contributed equally to this article. Ischemic stroke patients with t2dm and ckd were selected from the taiwan national health insurance research database nhird from march 1, 2009 to december 31. Overall, tecos results demonstrated that sitagliptin was noninferior to placebo with regard to its primary and secondary composite cv outcomes. The following conditions are contraindicated with this drug. Januvia sitagliptin in combination with metformin and a ppar. Sitagliptin phosphate is a drug used to treat diabetes mellitus type 2, and it belongs to a new therapeutic class called dipeptidyl peptidase iv inhibitors. Sitagliptin is used alone or together with other medicines eg, insulin, glimepiride, metformin, or pioglitazone and with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. Why did the fda refuse to add tecos data to sitagliptin label. Sitagliptin phosphate monohydrate is a white to offwhite, crystalline, nonhygroscopic powder.
10 1176 33 447 1149 680 355 725 1233 504 1488 219 432 549 212 950 1129 129 552 734 203 166 133 56 1389 8 1425 1430 938